Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
A specific immune response against the individual idiotypic determinants of clonal immunoglobulins can be elicited in patients with B-cell malignancies. We analyze the clinical outcome and the presence of tumor cells in the blood of 8 patients with follicular lymphoma, vaccinated with autologous idiotype protein from their lymphoma cells. After a median follow-up of 90 months (range: 54 to 128), all patients, except 1, remain in complete clinical remission and 5 are in complete molecular remission. Our results suggest that idiotype vaccination induces long-lasting clinical and molecular remissions and constitutes a potential curative treatment in follicular lymphoma patients.
Yáñez
Rosa
R
Department of Immunology, Hospital Clínica Puerta de Hierro, Madrid, Spain.
Barrios
Yvelise
Y
Ruiz
Elena
E
Cabrera
Rafael
R
Díaz-Espada
Fernando
F
D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis / Q000276:immunology; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D016233:Immunotherapy, Active; D008224:Lymphoma, Follicular / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D009360:Neoplastic Cells, Circulating / Q000276:immunology; D016133:Polymerase Chain Reaction; D012074:Remission Induction; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D004273:DNA, Neoplasm; D007130:Immunoglobulin Idiotypes